DelveInsight’s “Obsessive Compulsive Disorder Treatment Market Insights, Epidemiology and Market Forecast – 2034” report ...

Published in JAMA Network Open, the study reveals promising progress toward predicting how patients with major depressive disorder (MDD) will respond to antidepressant medications using brain imaging ...

Lindblad became the second rookie to win on the 2025 LPGA Tour, following Rio Takeda who won the Blue Bay LPGA in China. The Swede is the third Rolex First-Time Winner this season, joining Takeda ...

More than 50 years ago, PepsiCo (PEP) began making concentrate in Ireland because of the country’s low corporate tax rate, but that strategy is now backfiring as the concentrate for nearly all U ...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment ...

Needham & Company LLC upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a hold rating to a buy rating in a research note published on Tuesday, Marketbeat reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Use of crinecerfont (Crenessity, Neurocrine Biosciences), a CRF-1 receptor antagonist recently approved by the FDA, in individuals with CAH can lead to a decrease in glucocorticoid requirements.

Image: Gabriella Auchus. Printed with permission. The FDA in December approved crinecerfont (Crenessity, Neurocrine Biosciences) as an adjunct to glucocorticoid replacement to control androgens ...

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $179.00. Discover outperforming ...